Results 21 to 30 of about 218,065 (393)

An Aorta Intima Inhibitor of Platelet Aggregation [PDF]

Thrombosis and Haemostasis, 1977
The interaction of platelets and the vessel wall is of importance in the pathogenesis of intravascular thrombosis and atherosclerosis. We have previously described the presence of an inhibitor of platelet aggregation and a low Km ADPase in aorta intima extracts.
A. duP. Heyns, C. J. Badenhorst, Francois P. Retief   +2 more
openaire   +1 more source

Influence of Platelet Aggregation Modulators on Cyclic AMP Production in Human Thrombocytes

Folia Medica, 2018
Background: Cyclic AMP is a powerful inhibitor of platelet aggregation. In the present study we examined the effect of platelet aggregation modulators on cyclic AMP content in human thrombocytes.
Boyanov Krasimir O., Maneva Ana I.
doaj   +1 more source

Platelet aggregometry assay for evaluating the effects of platelet agonists and antiplatelet compounds on platelet function in vitro

MethodsX, 2019
Platelet aggregometry assays are generally used for the analysis of platelet function but can also be adapted for further research and therapy focused applications.
Alexandros Tsoupras, Ioannis Zabetakis, Ronan Lordan   +2 more
doaj   +1 more source

Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications [PDF]

, 2018
© The Author(s) 2018The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis.
A Gast, AD Michelson, B Labarthe, B Shen, C Patrono, CT Ammollo, D Capodanno, D Gailani, DA Gorog, Diana A. Gorog, DM Coenen, E Álvarez, ER Bates, F Kabirian, F Müller, F Semeraro, G Stephens, H Brogren, HE Speich, HE Speich, HJ Weiss, HJ Weiss, HR Baumgartner, J Zilberman-Rudenko, JD McFadyen, JI Weitz, JM Cosemans, JP Collet, JP Collet, K Hosokawa, K Nagatsuka, KS Sakariassen, L Valerio, LF Brass, M Cattaneo, M Farag, M Humbert, M Larsson, M Li, M Ungerer, MA Bailey, MI Furman, MJ Price, ML Montfoort von, MS Sabatine, P Andre, P Seizer, PA Borne von dem, PP Wadowski, R Hellmuth, R Nergiz-Unal, RA Ajjan, S Goto, S Goto, SA Shaya, SB Larsen, SJ Marciniak, T Heitzer, T Renné, VT Turitto, VT Turitto, WA Schumacher, WS Nesbitt, X Wang, Y Yano, YC Lau, ZM Ruggeri   +66 more
core   +2 more sources

Myricetin, the main flavonoid in Syzygium cumini leaf, is a novel inhibitor of platelet thiol isomerases PDI and ERp5 [PDF]

, 2020
Background: Flavonoids have been characterized as a prominent class of compounds to treat thrombotic diseases through the inhibition of thiol isomerases. Syzygium cumini is a flavonoid-rich medicinal plant that contains myricetin and gallic acid.
Ayyanar, Banno, Bekendam, Bi, Chagas, Chagas, Chang, Chen, Chung, Dang, De Bona, Dutta-Roy, Essex, Essex, Essex, Ghoshal, Giamogante, Giamogante, Holbrook, Inoue, Jarvis, Jasuja, Jayakumar, Jordan, Kang, Kehrel, Kim, Lahav, Lakowicz, Lescano, Lin, Lu, Mangin, Masuda, Navarro-Nuñez, Park, Raffaelli, Raturi, Sharma, Sousa, Stopa, Taylor, Trnkova, Wang, Ware, Wendelboe   +45 more
core   +1 more source

Comparison of the GPVI inhibitors losartan and honokiol

Platelets, 2020
Losartan and honokiol are small molecules which have been described to inhibit aggregation of platelets by collagen. Losartan has been proposed to block clustering of GPVI but not to affect binding of collagen. Honokiol has been reported to bind directly
Marie-Blanche Onselaer, Magdolna Nagy, Chiara Pallini, Jeremy A Pike, Gina Perrella, Lourdes Garcia Quintanilla, Johannes A Eble, Natalie S. Poulter, Johan W.M. Heemskerk, Steve P Watson   +9 more
doaj   +1 more source

Effects of the Btk-Inhibitors Remibrutinib (LOU064) and Rilzabrutinib (PRN1008) With Varying Btk Selectivity Over Tec on Platelet Aggregation and in vitro Bleeding Time

Frontiers in Cardiovascular Medicine, 2021
Background: Bruton tyrosine kinase inhibitors (BTKi) are used in B-cell malignancies and in development against various autoimmune diseases. Since Btk is also involved in specific pathways of platelet activation, BTKi might be considered to target ...
Rundan Duan, Luise Goldmann, Richard Brandl, Michael Spannagl, Christian Weber, Christian Weber, Christian Weber, Wolfgang Siess, Wolfgang Siess, Philipp von Hundelshausen, Philipp von Hundelshausen   +10 more
doaj   +1 more source

Serotonin reuptake inhibitors and cardiovascular disease [PDF]

, 2005
Selective serotonin re-uptake inhibiting drugs (SSRIs) are widely used for endogenous depression. In addition to depleting the nerve terminals of serotonin they also lower blood platelet serotonin levels.
Belcher, P.R., Drake-Holland, A.J., Noble, M.   +2 more
core   +1 more source

Continuation of medically necessary platelet aggregation inhibitors - acetylsalicylic acid and clopidogrel - during surgery for spinal degenerative disorders: Results in 100 patients

Surgical neurology international, 2014
Background: Patients undergoing spinal surgery while under anticoagulation therapy are at risk of developing bleeding complications, even though lower incidences have been reported for joint arthroplasty surgery.
R. Akhavan-Sigari, V. Rohde, M. Abili
semanticscholar   +1 more source

Human platelet activation by Escherichia coli: roles for FcγRIIA and integrin αIIbβ3 [PDF]

, 2016
Gram-negative Escherichia coli cause diseases such as sepsis and hemolytic uremic syndrome in which thrombotic disorders can be found. Direct platelet–bacterium interactions might contribute to some of these conditions; however, mechanisms of human ...
Arman, Mònica, Cox, Dermot, Henderson, Ian R., Kerrigan, Steven W., Watson, Callum N., Watson, Steve P.   +5 more
core   +3 more sources